These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28860008)

  • 1. A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing.
    Todd I; Negm OH; Reps J; Radford P; Figueredo G; McDermott EM; Drewe E; Powell RJ; Bainbridge S; Hamed M; Crouch S; Garibaldi J; St-Gallay S; Fairclough LC; Tighe PJ
    Pharmacol Res; 2017 Nov; 125(Pt B):188-200. PubMed ID: 28860008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS).
    Negm OH; Mannsperger HA; McDermott EM; Drewe E; Powell RJ; Todd I; Fairclough LC; Tighe PJ
    Eur J Immunol; 2014 Jul; 44(7):2096-110. PubMed ID: 24668260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome.
    Simon A; Park H; Maddipati R; Lobito AA; Bulua AC; Jackson AJ; Chae JJ; Ettinger R; de Koning HD; Cruz AC; Kastner DL; Komarow H; Siegel RM
    Proc Natl Acad Sci U S A; 2010 May; 107(21):9801-6. PubMed ID: 20457915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathway.
    Greco E; Aita A; Galozzi P; Gava A; Sfriso P; Negm OH; Tighe P; Caso F; Navaglia F; Dazzo E; De Bortoli M; Rampazzo A; Obici L; Donadei S; Merlini G; Plebani M; Todd I; Basso D; Punzi L
    Arthritis Res Ther; 2015 Apr; 17(1):93. PubMed ID: 25888769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAPS mutations in
    Akagi T; Hiramatsu-Asano S; Ikeda K; Hirano H; Tsuji S; Yahagi A; Iseki M; Matsuyama M; Mak TW; Nakano K; Ishihara K; Morita Y; Mukai T
    Front Immunol; 2022; 13():926175. PubMed ID: 35936010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) are hypersensitive to Toll-like receptor 9 stimulation.
    Negm OH; Singh S; Abduljabbar W; Hamed MR; Radford P; McDermott EM; Drewe E; Fairclough L; Todd I; Tighe PJ
    Clin Exp Immunol; 2019 Sep; 197(3):352-360. PubMed ID: 31009059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candidate genes in patients with autoinflammatory syndrome resembling tumor necrosis factor receptor-associated periodic syndrome without mutations in the TNFRSF1A gene.
    Borghini S; Fiore M; Di Duca M; Caroli F; Finetti M; Santamaria G; Ferlito F; Bua F; Picco P; Obici L; Martini A; Gattorno M; Ceccherini I
    J Rheumatol; 2011 Jul; 38(7):1378-84. PubMed ID: 21459945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS).
    Bachetti T; Chiesa S; Castagnola P; Bani D; Di Zanni E; Omenetti A; D'Osualdo A; Fraldi A; Ballabio A; Ravazzolo R; Martini A; Gattorno M; Ceccherini I
    Ann Rheum Dis; 2013 Jun; 72(6):1044-52. PubMed ID: 23117241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome.
    Pucino V; Lucherini OM; Perna F; Obici L; Merlini G; Cattalini M; La Torre F; Maggio MC; Lepore MT; Magnotti F; Galgani M; Galeazzi M; Marone G; De Rosa V; Talarico R; Cantarini L; Matarese G
    J Leukoc Biol; 2016 May; 99(5):761-9. PubMed ID: 26598380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNFR1-d2 carrying the p.(Thr79Met) pathogenic variant is a potential novel actor of TNFα/TNFR1 signalling regulation in the pathophysiology of TRAPS.
    Rittore C; Méchin D; Sanchez E; Marinèche L; Ea V; Soler S; Vereecke M; Mallavialle A; Richard E; Duroux-Richard I; Apparailly F; Touitou I; Grandemange S
    Sci Rep; 2021 Feb; 11(1):4172. PubMed ID: 33603056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS).
    Lobito AA; Kimberley FC; Muppidi JR; Komarow H; Jackson AJ; Hull KM; Kastner DL; Screaton GR; Siegel RM
    Blood; 2006 Aug; 108(4):1320-7. PubMed ID: 16684962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A.
    Nowlan ML; Drewe E; Bulsara H; Esposito N; Robins RA; Tighe PJ; Powell RJ; Todd I
    Rheumatology (Oxford); 2006 Jan; 45(1):31-7. PubMed ID: 16287931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of a novel G87V TNFRSF1A mutation in patients with TNF receptor-associated periodic syndrome.
    Tsuji S; Matsuzaki H; Iseki M; Nagasu A; Hirano H; Ishihara K; Ueda N; Honda Y; Horiuchi T; Nishikomori R; Morita Y; Mukai T
    Clin Exp Immunol; 2019 Dec; 198(3):416-429. PubMed ID: 31429073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel markers of inflammation identified in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) by transcriptomic analysis of effects of TRAPS-associated tumor necrosis factor receptor type I mutations in an endothelial cell line.
    Rebelo SL; Amel-Kashipaz MR; Radford PM; Bainbridge SE; Fiets R; Fang J; McDermott EM; Powell RJ; Todd I; Tighe PJ
    Arthritis Rheum; 2009 Jan; 60(1):269-80. PubMed ID: 19116900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome.
    Dickie LJ; Aziz AM; Savic S; Lucherini OM; Cantarini L; Geiler J; Wong CH; Coughlan R; Lane T; Lachmann HJ; Hawkins PN; Robinson PA; Emery P; McGonagle D; McDermott MF
    Ann Rheum Dis; 2012 Dec; 71(12):2035-43. PubMed ID: 22679299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour necrosis factor receptor I blockade shows that TNF-dependent and TNF-independent mechanisms synergise in TNF receptor associated periodic syndrome.
    Fairclough LC; Stoop AA; Negm OH; Radford PM; Tighe PJ; Todd I
    Eur J Immunol; 2015 Oct; 45(10):2937-44. PubMed ID: 26202849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profile in TNF receptor-associated periodic syndrome reveals constitutively enhanced pathways and new players in the underlying inflammation.
    Borghini S; Ferrera D; Prigione I; Fiore M; Ferraris C; Mirisola V; Amaro AA; Gueli I; Zammataro L; Gattorno M; Pfeffer U; Ceccherini I
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S121-S128. PubMed ID: 27310036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canakinumab for the treatment of TNF-receptor associated periodic syndrome.
    La Torre F; Caparello MC; Cimaz R
    Expert Rev Clin Immunol; 2017 Jun; 13(6):513-523. PubMed ID: 28454496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance of Serum Soluble TNF Receptor I/II Ratio for the Differential Diagnosis of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome From Other Autoinflammatory Diseases.
    Yasumura J; Shimizu M; Toma T; Yashiro M; Yachie A; Okada S
    Front Immunol; 2020; 11():576152. PubMed ID: 33162992
    [No Abstract]   [Full Text] [Related]  

  • 20. Revisiting TNF Receptor-Associated Periodic Syndrome (TRAPS): Current Perspectives.
    Cudrici C; Deuitch N; Aksentijevich I
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.